HomeCompareSMFR vs QYLD

SMFR vs QYLD: Dividend Comparison 2026

SMFR yields 643.92% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SMFR wins by $457922.45M in total portfolio value
10 years
SMFR
SMFR
● Live price
643.92%
Share price
$0.31
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$457922.48M
Annual income
$350,764,431,454.41
Full SMFR calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — SMFR vs QYLD

📍 SMFR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSMFRQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SMFR + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SMFR pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SMFR
Annual income on $10K today (after 15% tax)
$54,732.78/yr
After 10yr DRIP, annual income (after tax)
$298,149,766,736.25/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, SMFR beats the other by $298,149,761,925.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SMFR + QYLD for your $10,000?

SMFR: 50%QYLD: 50%
100% QYLD50/50100% SMFR
Portfolio after 10yr
$228961.25M
Annual income
$175,382,218,556.86/yr
Blended yield
76.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SMFR right now

SMFR
Analyst Ratings
2
Buy
2
Hold
Consensus: Buy
Price Target
$2.33
+650.2% upside vs current
Range: $1.00 — $3.00
Altman Z
-1.9
Piotroski
5/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SMFR buys
0
QYLD buys
0
No recent congressional trades found for SMFR or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSMFRQYLD
Forward yield643.92%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$457922.48M$25.4K
Annual income after 10y$350,764,431,454.41$5,659.31
Total dividends collected$449105.80M$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: SMFR vs QYLD ($10,000, DRIP)

YearSMFR PortfolioSMFR Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$75,092$64,391.50$10,352$1,192.36+$64.7KSMFR
2$532,241$451,892.93$10,830$1,347.57+$521.4KSMFR
3$3,562,928$2,993,430.52$11,460$1,539.07+$3.55MSMFR
4$22,540,026$18,727,693.09$12,275$1,777.84+$22.53MSMFR
5$134,843,380$110,725,551.39$13,323$2,078.95+$134.83MSMFR
6$763,351,740$619,069,323.81$14,667$2,463.34+$763.34MSMFR
7$4,092,082,536$3,275,296,174.56$16,396$2,960.57+$4092.07MSMFR
8$20,787,693,434$16,409,165,120.49$18,631$3,612.97+$20787.67MSMFR
9$100,147,705,392$77,904,873,416.94$21,548$4,482.15+$100147.68MSMFR
10$457,922,476,223$350,764,431,454.41$25,398$5,659.31+$457922.45MSMFR

SMFR vs QYLD: Complete Analysis 2026

SMFRStock

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.

Full SMFR Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this SMFR vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SMFR vs SCHDSMFR vs JEPISMFR vs OSMFR vs KOSMFR vs MAINSMFR vs XYLDSMFR vs JEPQSMFR vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.